1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 10,000 | 10,100 | 26.06. | |
| 9,650 | 10,400 | 26.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | MiNK Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 28.05. | MiNK Therapeutics behandelt ersten Patienten in Phase-2-Studie zu akuter Lungenschädigung | - | Investing.com Deutsch | ||
| 28.05. | MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness | 224 | GlobeNewswire (Europe) | First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteriaLandmark advances a first-in-class... ► Artikel lesen | |
| 20.05. | MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications | 183 | GlobeNewswire (Europe) | agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trialSequential immunotherapy with agenT-797 and N-803, an FDA-approved... ► Artikel lesen | |
| 15.05. | Earnings Call Transkript: MiNK Therapeutics zeigt in Q1 2026 strategische Fortschritte | 6 | Investing.com Deutsch | ||
| 15.05. | Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call | 2 | Benzinga.com | ||
| 15.05. | MiNK Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.05. | MiNK Therapeutics starts phase 2 trial for lung injury therapy | 1 | Investing.com | ||
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.05. | MiNK Therapeutics GAAP EPS of -$0.57 beats by $0.20 | 2 | Seeking Alpha | ||
| 15.05. | MiNK Therapeutics startet Phase-2-Studie für Therapie gegen akute Lungenschädigung | 1 | Investing.com Deutsch | ||
| 15.05. | MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation | 279 | GlobeNewswire (Europe) | Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026AACR and ASGCT presentations showcase... ► Artikel lesen | |
| 14.05. | MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness | 341 | GlobeNewswire (Europe) | Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung injury and hypoxemic respiratory failure Study initiates in Lviv, Ukraine... ► Artikel lesen | |
| 12.05. | MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 | 1 | GlobeNewswire (USA) | ||
| 08.05. | MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs | 2 | GlobeNewswire (USA) | ||
| 17.04. | MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer | 198 | GlobeNewswire (Europe) | First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset... ► Artikel lesen | |
| 03.04. | MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 | 1 | GlobeNewswire (USA) | ||
| 02.04. | MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy | 3 | GlobeNewswire (USA) | ||
| 31.03. | MiNK Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | MiNK Therapeutics GAAP EPS of -$0.56 beats by $0.12 | 6 | Seeking Alpha | ||
| 31.03. | MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum | 235 | GlobeNewswire (Europe) | ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000-300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,85 | -0,13 % | BioNTech-Aktie: Ist das Unternehmen noch zu retten? | Die Geschichte von BioNTech ist eine der größten Erfolgsgeschichten der deutschen Wirtschaft. Aus einem Mainzer Forschungsunternehmen wurde innerhalb weniger Jahre ein globaler Pharmakonzern, dessen... ► Artikel lesen | |
| BB BIOTECH | 51,50 | 0,00 % | EQS-NVR: BB BIOTECH AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: BB BIOTECH AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
BB BIOTECH AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| VALNEVA | 2,265 | -0,04 % | VALNEVA SE: Valneva Announces Successful Outcome of its Annual General Meeting | Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that... ► Artikel lesen | |
| NOVAVAX | 7,750 | -0,77 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| OCUGEN | 1,306 | +0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,969 | +0,68 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,300 | -0,30 % | Abnehm-Medikamente: Milliardenmarkt Adipositas: Der nächste Herausforderer für Novo und Lilly? | © Foto: JoNel Aleccia - picture alliance / ASSOCIATED PRESSViking Therapeutics startet die klinische Prüfung eines neuen Adipositas-Wirkstoffs. Damit wächst die Konkurrenz im Milliardenmarkt für Adipositas-Therapien.Viking... ► Artikel lesen | |
| INFLARX | 1,687 | -0,24 % | InflaRx NV im Höhenflug: Was hinter dem Kursanstieg wirklich steckt - Was ich konkret unternommen habe! | ||
| INTELLIA THERAPEUTICS | 14,120 | -3,42 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| EDITAS MEDICINE | 2,450 | -2,78 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,820 | +0,78 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,660 | -1,08 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,390 | -4,37 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,931 | +1,42 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| GERON | 1,139 | 0,00 % | Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights | Achieved $51.8 million in RYTELO- (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating... ► Artikel lesen |
Das Unternehmen MINK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -6,74 % bei einem Aktienkurs von 9,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.